58% of patients affected by 2022 mpox outbreak report lasting physical symptoms
.jpg){kind=link}
A cohort study found that more than half of those diagnosed with mpox during the 2022 outbreak still had lingering physical effects 11 to 18 months later.
Registered users, subscribers or members - SIGN IN
To continue reading this article
Membership
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
Register
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
Subscribe
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.